NCT02408562终止1 期
A Phase 1, Multicentre, Randomised, Double-blind Study to Assess Safety and Tolerability of Repeated Intracerebroventricular Administration of sNN0031 Infusion Solution to Patients With Parkinson's Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 10
- 主要终点
- Tolerability of sNN0031 [Number of Adverse Events (AE) and Serious Adverse Events (SAE) occurring in each group over the study duration]
研究概览
简要总结
This is a phase I, randomised, placebo-controlled study to assess the safety and tolerability of two 2-weeks cycles of i.c.v. administration of sNN0031 infusion solution to patients with PD of moderate severity with persisting on-off symptoms in spite of other PD medications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Disease duration ≥ 5 years (diagnosis based on medical history and neurological examination).
- •Male or female, age 30 - 75 years inclusive.
- •Motor fluctuations, with OFF-time >1.5 hours during the day
- •A Hoehn and Yahr stage of 2 to 4 during OFF phase
- •Score >22 on the UPDRS part III during ON phase
- •Patients should be L-dopa responsive and demonstrate at least a 30% decrease in the UPDRS part III score after administration of L-dopa (L-dopa challenge test)
- •Optimised and stable anti-Parkinson treatment for at least 3 months before screening
排除标准
- •The patient has any indication of forms of parkinsonism other than idiopathic Parkinson's disease
- •The patient is in a late stage of Parkinson's disease, and is experiencing severe, disabling peak-dose or biphasic dyskinesia and/or unpredictable or widely swinging fluctuations in their symptoms
- •Patients who are on treatment with Duodopa or Apomorphine pump at the time of screening
- •The patient has an implanted shunt for the drainage of CSF or an implanted Central Nervous System (CNS) catheter, or have received neurosurgical intervention related to PD (e.g. deep brain stimulation, thalamotomy etc.) or is scheduled to do so during the trial period
- •Concurrent diagnoses of dementia with a score of 24 or lower on Mini-Mental State Examination (MMSE).
- •The patient is depressed, as indicated by a Hamilton Depression Rating Scale (GRID-HAMD, 17-item scale) score > 17
- •Patients who are at high risk of suicide as judged by the rating of the Columbia Symptoms Suicide Rating Scale (C-SSRS)
- •Patients with a history of increased intracranial pressure
- •Ophthalmologic examination (funduscopy and visual acuity by Early Treatment of Diabetic Retinopathy Study (EDTRS) and perimetry) with clinically significant findings that imply safety concerns for this study
- •The patient has a current clinically significant gastrointestinal, renal, hepatic, endocrine, pulmonary or cardiovascular disease
- •The patient has heart problems or a significant ECG abnormality
- •Uncontrolled hypertension.
- •The patient has in the past experienced psychotic symptoms (e.g. schizophrenia or psychotic depression)
- •The patient has a mental or physical condition which would preclude performing study assessments
- •Alcohol or substance dependence within the prior 12 months, or abuse within 3 months, with the exceptions of nicotine
- •MRI examination with findings of tumours or potential sources of pathological bleedings, or any abnormality that may put the patient at risk
- •History of structural brain disease including tumours and hyperplasia
- •Ongoing or suspected primary or recurrent malignant disease (currently active or in remission for less than one year)
- •Any disorder that precludes a surgical procedure, alters wound healing or renders chronic i.c.v. delivery or device implants medically unsuitable
- •The patient has a history or a current diagnosis of HIV, Hepatitis B or C.
- •Increased susceptibility to infections
- •Women who are pregnant or breast feeding or unwilling to use adequate contraception during the trial (only women of child bearing potential)
结局指标
主要结局
Tolerability of sNN0031 [Number of Adverse Events (AE) and Serious Adverse Events (SAE) occurring in each group over the study duration]
时间窗: 10 months
Number of AEs and SAEs occurring in each group over the study duration
次要结局
- Peak concentrations of sNN0031 in cerebrospinal fluid during two 14 day continuous infusion cycles(14 days x 2)
- Pump flow error rate(10 months)
- Number of patients with AEs related to the Implanted Infusion System(10 months)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
1 期
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD SubjectsAsthma (Part 1)COPD (Part 2)NCT02573155AstraZeneca134
Unknown
1 期
Study of OsrhAAT or Placebo in Healthy VolunteersEmphysema Secondary to Congenital AATDNCT05315921Healthgen Biotechnology Corp.48
已完成
1 期
A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult SubjectsHealthy VolunteersNCT04680429Rhizen Pharmaceuticals SA42
已完成
1 期
Study of HBV-001 D1 in Healthy AdultsDengue FeverNCT00936429Hawaii Biotech, Inc.16
招募中
1 期
Study of HS-10517 in Chinese Adult ParticipantsCOVID-19NCT05779579Jiangsu Hansoh Pharmaceutical Co., Ltd.340